Skip to Content

Abstract on ˜Chemoablation of Metastatic Melanoma' Accepted for Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology

Dr. Sanjiv Agarwala to Present Clinical Data on May 15, 2009 in Vienna

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Apr 21, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the abstract “Chemoablation of metastatic melanoma with intralesional PV-10” has been accepted for oral presentation at the Joint Meeting of the 7th World Congress on Melanoma and the 5th Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria on May 15, 2009, as part of the “Free Communication 26- Clinical Studies V” portion of the program.

The presentation by Dr. Sanjiv Agarwala, M.D., a Principal Investigator for Provectus' Phase 2 study of PV-10 for metastatic melanoma, will include an update on progress of the Phase 2 study and extended survival data from the completed Phase 1 study of PV-10. Provectus' recently presented Interim Phase 2 results from the PV-10 study for metastatic melanoma indicated the efficacy and safety results are as good as or better than those results reported for Phase 1.

Dr. Craig Dees, PhD, CEO of Provectus said, “The acceptance of this abstract for a presentation at the World Congress on Melanoma/Congress of the EADO demonstrates the global medical community's interest in our research and PV-10's potential as a treatment for metastatic melanoma. With the World Health Organization having projected that 48,000 patients globally died from melanoma in 2008, there is clearly a need for new treatment alternatives for this deadly disease. We look forward to this presentation as well as to Dr. Agarwala's presentation at ASCO (May 29th through June 2nd), where he will present an abstract entitled, ˜Chemoablation of melanoma with intralesional rose bengal (PV-10).'”

About the “World Congress on Melanoma” and the “Congress of the European Association of Dermato-Oncology” (EADO) Meeting

These major interdisciplinary meetings for clinicians and basic scientists working in the fields of melanoma and non-melanoma skin cancer will be held together for the first time as a Joint Meeting covering the entire spectrum of cutaneous malignancies. Many of the world's leading investigators are scheduled to participate in the meeting, which will focus on the state of the art in prevention, recognition, and treatment of cutaneous neoplasms covering melanoma and non melanoma skin cancer as well as lymphomas and rare skin tumors.

About Provectus Pharmaceuticals, Inc. (

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP – Investor Relations
Bill Gordon, SVP – Media Relations

Posted: April 2009